Lido Advisors LLC Has $981,000 Position in United Therapeutics Corporation $UTHR

Lido Advisors LLC grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 156.7% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 1,653 shares of the biotechnology company’s stock after purchasing an additional 1,009 shares during the period. Lido Advisors LLC’s holdings in United Therapeutics were worth $981,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of UTHR. Torren Management LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management raised its holdings in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC boosted its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its position in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $530.42, for a total transaction of $5,038,990.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $172,091,056.06. This trade represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $552.56, for a total transaction of $4,586,248.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $24,960,240.32. This trade represents a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 512,833 shares of company stock worth $285,561,257. Company insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Morgan Stanley set a $516.00 price target on United Therapeutics in a research report on Thursday, May 7th. Bank of America decreased their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. HC Wainwright boosted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $648.33.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Wall Street maintains a generally constructive view: 11 analysts rate UTHR a Buy and two rate it Hold, producing a consensus “Moderate Buy” rating and an average price target of $648.33. JPMorgan recently raised its target to $687, while HC Wainwright lifted its target to $660. United Therapeutics Corporation Given Average Rating of Moderate Buy by Brokerages
• Positive Sentiment: Institutional investors continued adding to positions during the second quarter. Assenagon Asset Management increased its stake by 79.2%, and Versant Capital Management nearly doubled its position. Institutions collectively own about 94.1% of UTHR’s outstanding shares.
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.04 million at an average price of $530.42 on July 27. She retained 324,443 directly held shares valued at roughly $172 million, so the transaction reduced her direct position by 2.84% but does not represent an exit from the company. Insider Selling: United Therapeutics CEO Sells $5 Million of Stock
• Negative Sentiment: The CEO’s repeated recent share disposals may weigh on sentiment, particularly while UTHR trades below its 50-day and 200-day moving averages. However, insider sales can also reflect personal financial planning rather than a change in the company’s outlook.
• Negative Sentiment: United Therapeutics’ latest reported quarter showed weaker-than-expected results: earnings per share were $5.82 versus a $7.00 consensus estimate, revenue was $781.5 million versus $797.4 million expected, and revenue declined 1.6% year over year. These results remain a fundamental concern despite full-year earnings estimates of $26.65 per share.

United Therapeutics Stock Down 0.8%

Shares of NASDAQ UTHR opened at $523.63 on Wednesday. The business’s 50 day moving average price is $546.23 and its two-hundred day moving average price is $532.01. The company has a market cap of $22.23 billion, a PE ratio of 19.33, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same period in the previous year, the business earned $6.63 earnings per share. The business’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.